Experimental studies using OMV in a new platform of SARS-CoV-2 vaccines
human vacines & immunotherapeutics
;
17(9): 1-5, 2021.
Artigo
em Inglês
| LILACS, CONASS, ColecionaSUS, SES-SP, SESSP-IALPROD, SES-SP
| ID: biblio-1417874
ABSTRACT
Although COVID-19 vaccines have recently been approved for emergency use, search for new vaccines are still urgent, since the access of the countries, especially the poorest, to the vaccines, has shown to be slower than the necessary to rapidly control the pandemic. We proposed a novel platform for vaccine using recombinant receptor binding domain (rRBD) from Sars-Cov-2 spike protein and Neisseria meningitidis outer membrane vesicles (OMVs). The antigen preparation produced a humoral and cellular immune response. Taken together our findings suggest a good immunostimulatory patter in response to immunization with rRBD plus N. meningitidis OMV.
Texto completo:
DisponíveL
Índice:
LILACS (Américas)
Assunto principal:
Vacinas contra COVID-19
/
SARS-CoV-2
/
Imunidade Celular
/
Antígenos
/
Neisseria meningitidis
Idioma:
Inglês
Revista:
Human vacines & immunotherapeutics
Ano de publicação:
2021
Tipo de documento:
Artigo
Instituição/País de afiliação:
Animal Health Department, Embrapa Southern Region Animal Husbandry/BR
/
Department of Immunology/BR
Similares
MEDLINE
...
LILACS
LIS